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Abstract A mini-symposium was held in Montreal,
Canada, at the International Surgical Week for the Breast
Surgical International in 2007 addressing the question
whether breast cancer is the same disease in Asian and
Western countries. Numerous investigators from Asian and
Western countries presented the epidemiologic and clinical
outcome data of women with breast cancer. Although there
are signiﬁcant similarities, the striking difference is that the
peak age for breast cancer is between 40 and 50 years in
the Asian countries, whereas the peak age in the Western
countries is between 60 and 70 years. Also, the incidence
of breast cancer in Asia is rising and is associated with
increased mortality. In the West, although the incidence is
increasing, the mortality rate is deﬁnitely decreasing.
Future prospective data collection from Asian and Western
countries may provide further interesting epidemiologic
and outcome data regarding the outcome of women with
breast cancer from Asian and Western countries.
Background Whether breast cancer is the same disease in
Asian and Western countries was the topic of a 2007 Breast
Surgery International symposium at International Surgical
Week.
Methods Participating investigators from China, Taiwan,
India, Japan, South Korea, Sweden, Canada, and the United
States were asked beforehand to provide data on the epi-
demiology and treatment outcome of women in their
countries.
Results Comparisons of the epidemiologic and clinical
outcome data of women with breast cancer showed sig-
niﬁcant similarities, but the striking difference is that the
peak age is between 40 and 50 years in Asian countries,
but is between 60 and 70 years in Western countries.
S. P. L. Leong (&)
Department of Surgery, California Paciﬁc Medical Center and
Sutter Paciﬁc Medical Foundation, 2340 Clay Street, 2nd Floor,
San Francisco, CA 94115, USA
e-mail: leongsx@cpmcri.org
Z.-Z. Shen
Department of Surgery, Fudan University,
Shanghai, People’s Republic of China
T.-J. Liu
Department of Surgery, Taipei Medical University,
Wanfang Medical Center, Taipei, Taiwan
G. Agarwal
Department of Endocrine and Breast Surgery, Sanjay Gupta
Postgraduate Institute of Medical Sciences, (SGPGIMS),
Lucknow 226014, India
T. Tajima
Department of Surgery, Tokai University, Tokyo, Japan
N.-S. Paik
Department of Surgical Oncology, Korea Cancer Center
Hospital, Seoul, South Korea
K. Sandelin
Deparment of Molecular Medicine and Surgery, Karolinska
Institutet, Stockholm, Sweden
A. Derossis
Department of Surgery, McGill University, Montreal, Canada
H. Cody
Department of Surgery, Memorial Sloan-Kettering Hospital,
New York, NY, USA
W. D. Foulkes
Department of Medicine, McGill University, Montreal,
Canada
123
World J Surg (2010) 34:2308–2324
DOI 10.1007/s00268-010-0683-1The incidence of breast cancer in Asia is rising and is
associated with increased mortality. In the West, although
the incidence is also increasing, the mortality rate is deﬁ-
nitely decreasing.
Discussion Future prospective data collection from Asian
and Western countries may provide further interesting
epidemiologic and outcome data regarding the outcome of
women with breast cancer from Asian and Western
countries.
Introduction
Although the incidence of breast cancer has increased
globally over the last several decades [1–3], the greatest
increase has been in Asian countries [4]. In Asia, breast
cancer incidence peaks among women in their forties [4],
whereas in the United States and Europe, it peaks among
women in their sixties. This variation in incidence may be
due to multiple factors, including geographic variation,
racial/ethnic background, genetic variation, lifestyle,
environmental factors, socioeconomic status, the presence
of known risk factors, utilization of screening mammog-
raphy, stage of disease at diagnosis, and the availability of
appropriate care [2]. Whether these discrepancies indicate
that breast cancer is the same disease in Asia as it is in
Western countries was the topic of a Breast Surgery
International (BSI) symposium attended by surgeons from
many countries during the 2007 Montreal International
Surgical Week. To discern whether breast cancer charac-
teristics other than incidence differ between Asian and
Western countries, breast cancer experts from China,
Taiwan, India, Japan, South Korea, Europe, Canada, and
the United States summarized their experiences in this
report.
Materials and methods
Experts from the various countries who participated in the
symposium were asked beforehand to complete a table
containing multiple questions (Table 1). Participating
investigators represented China, Taiwan, India, Japan,
South Korea, Sweden, Canada, and the United States. Each
investigator was also asked to write a summary of how the
data requested in the table were collected.
Results
Data for every question were not available for all countries
participating in the symposium. The following summaries
are presented by the representative from each country.
China
Data collection and incidence estimates
There is a lack of countrywide effort to collect data on
breast cancer in China. Most data have been obtained from
cities and suburban areas such as Shanghai, Beijing, Harbin,
Wuhan, and Qigong. The data from these areas are evalu-
ated by the Statistics Center within the Health Ministry of
the People’s Republic of China. Shanghai’s Municipal
Center for Disease Control and Prevention (CDCP) plays an
active role in cancer surveillance. Most data published in
China come from the Shanghai CDCP and Fudan Univer-
sity Cancer Hospital, or from articles published in China.
Data from Fudan University are derived from a database
established by the Department of Breast Surgery, which has
collected more than 10,000 records of patients, includ-
ing detailed clinical and pathologic data with follow-up
information.
Incidence estimates vary for China. China’s Health
Ministry data indicate an incidence of 24/100,000.
According to global cancer statistics for the year 2002 [5],
the age-standardized incidence for breast cancer is 18.7/
100,000 in China. However, in Shanghai, the incidence is
considerably higher, at 61/100,000; after age standardiza-
tion, the incidence is 37/100,000 (2003 data from Shanghai
CDCP). Data from Shanghai’s CDCP showed that in 2003,
the age distribution of breast cancer patients in China was
different from that in the West, with a peak among women
45–50 years old.
Screening and methods of detection
Data from Fudan University Cancer Hospital show that
breast self-examination is recommended to cancer patients
and healthy women. It is recommended that women over
the age of 40 have a mammogram each year. The breast
cancer screening program is carried out well in urban
Shanghai.
AJCC stage of initial presentation
In Fudan Cancer Hospital, stage II is the most common
stage of newly diagnosed breast cancer, accounting for
about 50% of cases. The percentage of newly diagnosed
stage I breast cancers is up to 20% and still increasing,
whereas the percentage of stage III breast cancers has
decreased from 40% in the 1970s to 20% in 1990s.
Treatment
In China, surgical treatment for breast cancer varies in
different provinces and areas, and even varies within the
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123same area. The proportion of breast-conserving surgery is
15–30% in leading hospitals and has gradually increased in
recent years, according to studies published in China. But
the breast-conserving surgery rate is still low in China’s
general hospitals. Sentinel lymph node biopsy is starting to
be prevalent in urban areas, but it has not been accepted by
most early-stage breast cancer patients. The prevalence of
sentinel lymph node biopsy is less than 5%.
Data from Fudan University Cancer Hospital indicate
that an anthracycline-based chemotherapy regimen, which
gradually replaced the 1990s regimen of cytoxan, metho-
trexate, and 5-ﬂuorouracil (5-FU), has become the most
commonly used regimen for breast cancer in China. The
taxane-containing regimen is used for node-positive dis-
ease. Herceptin is used, although not very commonly, for
patients with tumors in which HER-2 is overexpressed or
ampliﬁed. The indication of adjuvant chemotherapy is
referred to St. Gallen 2005 consensus [6]. It is recom-
mended that all patients with ER/PR-positive tumors
receive endocrine therapy and that patients at high risk for
local-regional recurrence receive postoperative radiation
therapy.
Survival
In terms of survival, data from Fudan University Cancer
Hospital represent the survival rates in Shanghai and some
developing areas in China, but not the entire country. The
Fudan experiences showed a 5-year disease-free survival
rate of 76.5% and an overall survival rate of 87.6%. Ten-
year disease-free survival decreased to 61% and overall
survival to 78.9%. For patients with stage I, II, and III
disease, the 5-year disease-free survival was 88% and
overall survival was 94, 71 and 84%, and 48 and 64%,
respectively.
Taiwan
Data collection and incidence estimates
In Taiwan, incidence estimates are based on data from the
Bureau of Health Promotion, in the Department of Health.
The incidence of breast cancer in Taiwan has increased
from 6.23 per 100,000 in 1970 to 23.76 in 2000. Among
all types of cancer reported in 2005, the incidence of
breast cancer was the second most frequent cancer in
women after age adjustment of 42.3 per 100,000. It was
the number-one killer in women with invasive cancer.
The data from Taiwan’s nationwide cancer registration
system [7] reported 5,585 newly pathology-proven breast
cancer cases in 2005. Incidence peaks in women 40–
50 years old and the median age was 45. Cases in men
are extremely rare, and the ratio of males to females is
0.3:100. Only 2.6% of patients had ﬁrst-grade relative
involvement by breast cancer.
Screening and methods of detection
Several targeted screening programs have been imple-
mented since Taiwan’s Bureau of Health Promotion began
nationwide breast cancer screening in 1994. The ﬁrst
screening strategy was carried out in 12 major teaching
hospitals for the mothers, daughters, and sisters of patients
with breast cancer. The screening method consisted of
palpation by a breast surgeon and a mammogram and
sonogram once a year for 3 consecutive years (1994–1997).
A total of 83 cases of breast cancer were conﬁrmed in 966
abnormal ﬁndings out of 4,861 families at the ﬁrst visit.
Another 15 cases were diagnosed in 797 abnormal ﬁndings
out of 3,775 families at the second follow-up visit.
The second screening strategy (1999–2001) was carried
out by public health ofﬁcers for each county, who, together
with volunteer breast cancer patients, recruited all female
residents over 35 years of age in the county, to be exam-
ined by either a breast surgeon or a nurse at the screening
location, usually the county’s recreation center or a school.
Women also had a cervical smear testing and a stool occult
blood examination. A total of 452 breast cancer patients
were diagnosed in 42,522 abnormal ﬁndings out of 852,824
females at the ﬁrst visit, and 40 additional cancer cases
were found in 12,078 abnormal ﬁndings out of 122,278
females at the second visit. Some of the screening teams
from interested hospitals provided two additional sono-
grams during the screening period. The ﬁrst resulted in
detection of 212 breast cancer cases among 9,215 abnormal
ﬁndings out of 32,102 women. The second resulted in
another 40 cases diagnosed from 1,600 abnormal ﬁndings
out of 4,091 women.
The third screening strategy (2004–2007) was focused
on women between 40 and 49 years of age because they
have the highest incidence of breast cancer in Taiwan.
Because screening sonograms require clinical validation
and Asian women tend to have small, dense breasts, the
detection method was either a mammogram or a sonogram
in the ﬁrst year (Huang (2006) Randomized trial for breast
cancer screening with either mammography or ultrasound
among young women in Taiwan, unpublished data). The
screening procedure was then alternated in subsequent
years. Any abnormal ﬁnding was veriﬁed by palpation by
the breast surgeon, along with other necessary diagnostic
procedures. The ﬁrst year of sonogram screening resulted
in 20 proven breast cancer cases from 9,262 abnormal
ﬁndings from 17,471 women. Mammography resulted in
26 proven breast cancer cases from 9,235 abnormal ﬁnd-
ings from 16,565 women. After three cases in each group
were excluded because the patients refused surgical
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123treatment, postoperative pathological examination showed
ductile carcinoma in situ (DCIS) only, tumor\1.5 cm and
lymph node negative, tumor [1.5 cm or lymph node
positive by sonogram was 1/10/6, whereas by mammo-
gram, the ﬁnding was 10/5/8. When this screening program
was expanded to include mammograms for women
between the ages of 50 and 69, 141,873 had mammograms
and 15,336 (10.8%) were reported as BI-RAD category 0,
4, or 5. About 75% of patients with BI-RAD category 4 and
5( n = 11,502) had biopsies, and 499 were proven to have
breast cancer.
Treatment
A team approach has been employed for breast cancer
treatment in Taiwan. Breast surgeons, medical and radia-
tion oncologists, social workers, and rehabilitation per-
sonnel work together under clear guidelines to obtain the
best therapeutic result. The Oncology Group of the
National Health Research Institute of Taiwan (a govern-
ment institute under the Department of Health), published
the ﬁrst edition of guidelines for breast cancer management
in 2001 and a second edition in 2005 [8].
The guidelines were distributed in English to all phy-
sicians and were distributed in Chinese to the public. The
Bureau of Health Promotion reported in 2005 that for 5,585
newly diagnosed breast cancer cases, which were properly
recorded, partial mastectomy was performed in 18.6% of
all patients and 31.1% of patients with stage 0 and stage I
disease. Routine axillary lymph node dissection was per-
formed for all surgical patients.
Sentinel lymph node biopsy was validated in 1998 from
a single institute, and an additional 14 hospitals have
adopted this technique [9]. A nationwide questionnaire
survey regarding sentinel node biopsy in 3,367 cT1-
2N0M0 patients found that breast surgeons could obtain a
false negative rate within 5% after they accumulated
experience using sentinel lymph node biopsy in 100 cases.
Nevertheless, less than one-ﬁfth of cases with negative
biopsy results had omitted total axillary lymph node dis-
section due to medical-legal considerations.
Both preoperative and postoperative adjuvant chemo-
therapy are available in every hospital that follows the
NCCN’s Breast Cancer Therapeutic. All drugs for che-
motherapy have an approval certiﬁcation from the U.S.
Food and Drug Administration. Every patient who under-
went partial mastectomy received postoperative radiation
therapy, and sometimes other areas were irradiated,
according to the guidelines. Use of targeted therapy
depends on the results of HER-2/neu gene testing with the
DAKO method. These results appear as a routine patho-
logical report in the majority of hospitals in Taiwan.
Hormonal manipulation is a routine postoperative therapy
in women whose estrogen and progesterone receptors are
positive.
Survival
Bureau of Health Promotion data from 1998–2002 indicate
that 5-year survival for all stages was 78.37%. The 5- and
10-year survival rates are 98 and 95% for stage 0; 96 and
89% for stage I; 90 and 82% for stage II; 65 and 53% for
stage III; and 22 and 10% for stage IV.
India
Data collection and incidence estimates
India has no available source of comprehensive epidemio-
logical, clinicopathological, and outcomes data for breast
cancer patients. As a result, a variety of resources had to be
reviewedtoobtainrelevantdata,someofwhichareprovided
here. When no robust data source could be found, available
estimatesareprovided.Demographic,clinical,pathological,
and outcomes data on breast cancer patients managed at the
Sanjay Gupta Postgraduate Institute of Medical Sciences
(SGPGIMS) hospital in Lucknow, India, were collected and
analyzed. We also reviewed similar data, and data on
availability of breast screening, treatment facilities, and
outcomes from other major cancer centers and cancer reg-
istries of India. India’s national cancer registry program,
under the Indian Council of Medical Research, published a
2-year (1999–2000) report of hospital-based cancer regis-
tries,anda2-year(also1999–2000)reportofthepopulation-
based cancer registries. These reports assessed the burden
and care of cancer patients in India [10, 11]. In addition,
district-wide distributionof breast cancers was derived from
the All India Report 2001–2002, which was part of an atlas
of cancer in India project of the National Cancer Registry
Program, ICMR and is available at their web site:
www.canceratlasindia.org/chapter6 [12]. We searched the
published literature to obtain information on breast cancer
demographics, detection, treatment, and outcomes from
various Indian centers. We also searched the Internet, and
other publications of cancer registries and organizations
such as the World Health Organization, regional and
national health agencies, and institutions and non-govern-
mental organizations, among others. Appropriate similar
publications and reports from the International Agency for
Research on Cancer [13], and its GLOBOCAN database
[14] were also studied. The SGPGI breast cancer database
provided valid and complete information on 544 patients
managed during 1998–2004 at SGPGIMS in Lucknow,
India. Data from TMH, Mumbai, another dedicated breast
center in India, have been incorporated so that results can be
compared.
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cers in Indian women and about half of all cancer-related
deaths. With the exception of Chennai, all urban popula-
tion-based registries in India reported breast cancer as the
most common female malignancy over the years 2000–
2001[10–12]. In earlier reports, cancer of the uterine cervix
was the most common type of cancer, even in urban cen-
ters. Breast cancer remains second after cervical cancer as
the most common female malignancy reported in Chen-
nai’s urban population-based cancer registry and in Bar-
shi’s rural population-based registry [12]. Data from all
urban and rural population-based cancer registries in India
suggest a rising incidence of breast cancer in India. Yet, the
age-adjusted rates reported from various urban registries
range from 24.8 to 33.4 per 100,000 [12], which is about
one-third the incidence reported from Western countries
such as the United States (California SF: NH White, 109.6
per 100,000) and Uruguay (Montevideo, 114.9 per
100,000) [13]. The minimum age-adjusted rates reported
from the only rural population-based cancer registry in
India is even lower, at a mere 7.2 per 100,000 [12], and is
somewhat similar to the incidence reported from other
developing countries, such as The Gambia and Jiashan,
China [13].
In India, breast cancer incidence peaks among women
45–50 years of age. The average age of patients in six
hospital-based cancer registries ranged from 44.2 in
Dibrugarh, 46.8 in Delhi, 47 in Jaipur to 49.6 in Bangalore
and Chennai [12]. Among patients at SGPGIMS in Luc-
know, 26% were younger than 35 years of age, whereas at
TMH, Mumbai, this percentage was 11% [12].
Screening and methods of detection
An organized large-scale breast cancer screening program
does not exist in India. The few breast cancer screening
programs available are largely targeted at small commu-
nities, covering a miniscule proportion of the Indian pop-
ulation, and they rely on funds derived from research grants
or the screened individuals’ own resources. There is no
government-funded or aided mass breast screening pro-
gram available; experts also advocate screening based on
periodic breast examination by a physician and breast self-
examination [15]. Population-based breast cancer screen-
ing is not recommended in India due to limited resources
and the lack of local statistics on mammography and breast
cancers.
Nearly all Indian breast cancers are clinically detected;
almost none are detected by screening. Up to two-thirds of
patients present with local invasion, and 6–25% present
with metastases. Signiﬁcant proportions present with
T2/T3 tumors, and even more strikingly, up to one-third of
all patients have skin and/or chest wall involvement
(T4a-c). Inﬂammatory breast cancers are seen more often
in younger patients, putting them at considerably poor risk
for survival. Half of the young patients managed at
SGPGIMS, have stage III disease. The stage distribution of
patients is worse among younger women [16].
Pathologic characteristics
In India, a large proportion of patients have high-grade
tumors and hormone-receptor- negative tumors. About
60% of SGPGIMS breast cancer patients have grade 3
tumors, 66% have auxiliary lymph node metastases, and
58% are both estrogen (ER) and progesterone (PR)
receptor-negative. Data from Mumbai shows a slightly
lower ER- and PR-negative rate of 47% [17]. Data on
HER-2neu immuno-reactivity are scarce, but the available
information hints at low rates of positive HER-2neu status:
17% of 100 breast cancer patients recently treated at
SGPGIMS were found by immunohistochemistry to over-
express HER-2neu. On the whole, women younger than
35 years of age presented with larger tumors and at a later
stage. They were also more likely to be ER-negative and to
have a higher grade of cancer compared to the overall
average.
Treatment
The standard of treatment and the infrastructure and
facilities for treatment of breast cancer vary widely at
various Indian hospitals. A nationally applicable standard
is lacking, so the treatment available for an individual
patient may vary from world-class to very ordinary or even
inadequate. The ﬁrst WHO-ICMR national breast cancer
management guidelines meeting was held in an attempt to
evolve nationally applicable treatment protocols and rec-
ommendations, taking into account the available data on
breast cancer patients, and also keeping the logistics and
economics in mind [18]. Only a very few patients can be
considered to have received treatment at well-equipped
centers that use appropriate clinical protocols. A number of
compromises are made at every step of management of a
patient, including the diagnostic work-up, surgical treat-
ment, and the multi-modality therapy. For the huge Indian
population of over one billion, the numbers of treatment
facilities are grossly inadequate. This, along with the poor
patient compliance with treatment and follow-up due to the
social stigma attached to the disease, and the high cost of
treatment [19], limits the effectiveness of care. Fine needle
aspiration cytology is underutilized, and the preoperative
diagnosis is still based predominantly on clinical and
incisional or excisional biopsy. The standard of breast
pathology reporting too is erratic, and may range from very
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patient receives treatment. A signiﬁcant proportion of
patients undergo an incomplete or inappropriate surgical
excision before they are referred to a specialist, making
management challenging. At a major North Indian teaching
hospital, 75% of the patients had undergone an incisional
or excisional biopsy not intended for treatment of breast
cancer before they were referred for management of early
operable breast cancers [20]. At SGPGIMS, Lucknow,
some 40% patients with early or locally advanced breast
cancers are referred following an inadequate or inappro-
priate initial surgical procedure. Mastectomy after or
without neoadjuvant chemotherapy is usually offered for
all stages of breast cancers [21]. Completeness of mas-
tectomy and that of axillary clearance if performed is
questionable. Postmastectomy reconstruction is neither
offered to nor accepted by most patients, as it is seen as an
unnecessary burden on patient’s resources.
Breast-conservation surgery (BCS) is available to
patients treated at only a few selected hospitals in India,
and it is performed in only about 1,000 of the estimated
100,000 breast cancer patients treated for breast cancer
every year in India. Such low numbers of breast-con-
serving procedures are due to the relatively late stage at
presentation, the few centers equipped to provide high-
quality breast-conserving surgery with all its components
(including radiation therapy and pathology), as well as to
the low acceptance rate among patients [22, 23]. At
selected centers of excellence, with adequate counseling,
higher proportions of cancer patients with early and post-
neoadjuvant chemotherapy for locally advanced disease
accept breast conservation. At SGPGIMS Lucknow, and
at the Breast Unit at TMH Mumbai almost 60% of early
breast cancer patients are treated with BCS. Both these
centers have reported that the proportion of patients
undergoing BCS has been increasing, and at Mumbai,
this proportion increased from 12.6 % in 1997 to 59.3%
in 2001 [24]. Breast-conserving surgery is also being
offered to patients with locally advanced breast cancer
after neoadjuvant chemotherapy, with novel innovations
to make BCS practical and safer in large locally
advanced breast cancer patients [23]. Sentinel lymph
node biopsy is performed at very few centers, and it is
estimated that only about 500 patients per year undergo
this procedure.
Systemic and adjuvant treatment of breast cancer varies
in availability, use, and standards between various centers
in India, with a wide variety of chemotherapy regimens in
use. Although most physicians agree that anthracycline-
based chemotherapy combinations are an appropriate ﬁrst-
line approach to most patients, the cytoxan, methotrexate,
and 5-FU (CMF) combination is still used in a large pro-
portion as ﬁrst-line therapy because of its low cost. At a
community hospital in South India, of 122 breast cancer
patients treated, 5-FU, Adriamycin, cytoxan (FAC) regi-
men was used in 51.2% and CMF in 48.8 % patients [21].
Taxanes are used in a few patients, with their use limited
by their high costs and toxicity. Tamoxifen is the most
widely used endocrine therapy, and the proportion of
postmenopausal patients treated with aromatase inhibitors,
though increasing, is very small. Surgical oophorectomy is
still a widely practiced and valid choice in the vast majority
of hormone responsive premenopausal and advanced stage
breast cancer patients. Radiation ablation and goserlin are
relatively less effective and expensive. Targeted therapies
like trastuzumab are out of reach for most Indian patients.
There are very few radiation therapy units, and as a result
only about 20% of patients are treated with postmastec-
tomy radiation. The lack of adequate numbers of radiation
therapy facilities is a major hurdle in setting up more
breast-conservation therapy programs. Compliance with
adjuvant treatment among Indian patients outside major
institutions is rather poor due to the high cost, extended
treatment duration, and toxicity [25, 26].
Survival and mortality estimates
Although the incidence of breast cancer in India is lower
than that in Western countries, the mortality rates are
disproportionately higher [25, 26]. Thus breast cancer
remains the single largest cause for cancer deaths in
Indian women, similar to the rest of the world. Globally,
it accounts for about 15% of all cancer deaths in women,
killing some 471.2 women per 100,000 annually [18].
The 5-year survival rate of breast cancer patients repor-
ted at Bangalore’s population-based cancer registry was
42.3% [27]. The Madras Metropolitan Tumor Registry
reported survival rates of 80, 58, and 48% at 1 year,
3 years, and 5 years, respectively [28]. The 5-year
overall survival rate for patients treated and followed at
SGPGIMS Lucknow is 62%, with the 5-year survival
rate of 90% for stage I, 78% for stage II, 57% for stage
III, and 22% for stage IV patients. The overall 10-year
estimated survival of SGPGIMS Lucknow patients was
35%; with a 10-year survival rate of 75% for stage I,
55% for stage II, 35% for stage III, and 5% for stage IV
patients [25, 26].
Japan
Data collection and incidence estimates
There is no nationwide cancer registry in Japan. All clinical
data has been collected as cases registered by the Japanese
Breast Cancer Society. In 2004, 14,749 cases were regis-
tered. Survival data has been collected since 1992, with a
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123total of 2,320 cases as of 1992. (http://www.jbcs.gr.jp/
english/english.html). In 2005, the number of new cases
per year was estimated to be 41,490. The percentage of the
entire population of Japanese women estimated to have
breast cancer was 0.06%. Since 1998, breast cancer is the
most common cancer among women with an age-adjusted
rate of 43.6 in 1998. Breast cancer incidence peaks in
women between 45 and 49 years of age. The ratio of breast
cancer incidence in Japan to the U.S. is 1:3. The incidence
of male breast cancer is estimated at 0.4%, based on 2,320
cases registered in Japan Cancer Society in 1992.
Stage of initial presentation
According to the Japan Breast Cancer Society, among
14,166 registered cases, 43.6% presented with stage II
disease.
Screening and methods of detection
Screening mammography has been used. For women over
40, it was recommended by the Japanese Breast Cancer
Society that they have a mammography once every 2 years.
Self examination has also been recommended. A healthcare
taker examination was not available.
Treatment
According to statistics from the Japanese Breast Cancer
Society in 2003, 48.4% of patients had lumpectomy and
sentinel lymph node biopsy or axillary lymph node dis-
section, 45.3% had modiﬁed radical mastectomy, and
1–2% had extended radical mastectomy. Postoperative
therapy includes radiation, chemotherapy, and hormonal
therapy for all patients as needed.
Survival and mortality estimates
The overall 5-year survival rate is 82.2% and ranges
from 73.1 to 86.1% among the 14 cancer hospitals con-
tributing data. The crude breast cancer survival rate based
on this data correlates with tumor size. With 5.1 cm at
approximately 50%, and 0.5–2 cm the crude 5-year sur-
vival rate is about 90% and the disease-free 10-year
survival is 65–77%. Although breast cancer deaths in the
U.S. have decreased in the past 40 years, according to
data from the U.S. SEER program in 2001, deaths from
breast cancer continue to increase in Japan, according to
the Japanese Government’s Health and Welfare statistics
in 2003. In 2005, total deaths due to breast cancer were
estimated to be 10,808. The death rate was 10.8 per
100,000 populations, a 6.46-fold increase from 1950 to
2000 [29].
South Korea
Data collection and incidence estimates
The incidence of breast cancer in South Korea has con-
tinuously increased in recent years. Breast cancer has
emerged as the most frequent malignancy among Korean
women since 2001. The Ministry of Health and Welfare of
the Republic of Korea started the Korea Cancer Center
Registry (http://www.kbcs.or.kr) in 1980 and established a
National Cancer Incidence Database [30].
The Korean Breast Cancer Society (KBCS) has been
conducting a nationwide survey on breast cancer and its
clinical and epidemiological characteristics since 1996, in
the form of recorded cancer registration sheets. In 2001, an
on-line registration program was started, and 39 medical
schools (71 hospitals), 27 general hospitals, and 7 private
clinics now participate in this program. To date, 46,667
cases from the on-line registration program were analyzed
and reported in 2006 [30]. The collection and management
of survival data was conducted with the Korean Breast
Cancer Society (KBCS). Survival was analyzed from a
total of 49,174 cases from 1993 to 2003.
Breast cancer is the ﬁfth leading primary cancer in South
Korea, but has been the most frequent malignancy among
Korean women since 2001. Since 1996, the incidence of
breast cancer has increased steadily, from 3,801 cases in
1996 to 9,668 newly diagnosed cases in 2004. The accrued
incidence rate of breast cancer in 2004 was 40.5 per 100,000
with an increase since 1996 of 16.7 per 100,000. In Korea,
breast cancer incidence peaks between the ages of 40 and
49 years (median: 47 years). In 2004, 60% of women
diagnosed with breast cancer were pre-menopausal.
AJCC stage of initial presentation
Most of the women—about 60%—presented with a painless
lump. Asymptomatic breast cancer was detected on
screening 18% of the time. The diagnosis was made by ﬁne
needle aspiration 27% of the time. Invasive carcinoma
incidence was 87% and that of ductal carcinoma in situ
(DCIS) was 8.5%. According to the American Joint Cancer
Commission (AJCC) staging system, breast cancer in South
Korea is diagnosed as stage II in about 40% of cases.
Approximately 5.1% of patients are diagnosed as stage IIIC.
The proportion of early cancers diagnosed as stage I has
increased strikingly, from 19.6% in 1996 to 36% in 2004.
Treatment
Modiﬁed radical mastectomy was performed most fre-
quentlyinthe1990s,butitsusehasdecreasedfrom79.7%in
1996 to 54% in 2006. The use of breast-conserving therapy
2316 World J Surg (2010) 34:2308–2324
123hasbeen rapidlyincreasing,from18.7%in1996to42.6%in
2006. Sentinel lymph node biopsy has been used with
increasing frequency. The rate of reconstruction after mas-
tectomy is 8.5%.
Survival
From 1993 to 2002, a total of 49,417 cases were analyzed,
46,355 of which were invasive cancer and 2,819 of which
were noninvasive [31, 32].
The 5-year survival rate for invasive breast cancer was
80.3%; 10-year survival was 70.3%. For DCIS, the 5-year
survival rate was 99%. The increase in survival may be due
to the increase of early breast cancer detection and better
treatments. The 5-year survival rate for Korea is similar to
that of Japan but lower than that of United States.
Sweden
Data collection and incidence estimates
Data on patients treated for breast cancer are gathered
through the oncologic centers in six geographical regions
and reported to the Swedish Cancer Register. Details
regarding diagnosis, actual treatment details, and pathology
and adjuvant treatment are available for each region.
Sweden’s National Board of Health and Welfare is
responsible for ofﬁcial statistics [33]. Breast cancer in
Sweden accounts for 30% of all female cancers, and 0.2%
of all male cancers. The annual increase in breast cancer is
1.5 % over a 20-year period and 1.6 for a 10-year period.
Screening and methods of detection
In Sweden, screening is offered to women between the ages
of 40 and 74 where the regional county makes decisions on
age groups 40–49 and 70–74. Screening compliance is
approximately 65–80%, and is lower in urban areas and
higher in rural areas. Self-examination or exams performed
by healthcare workers is not recommended.
AJCC stage of initial presentation
In the Stockholm Gotland region in 2006, 1,524 new cases
of breast cancer were registered. There were 1,385 cases of
invasive carcinomas and 139 non invasive. Fifty-six per-
cent of the invasive cancers were stage I, 37% stage II, 5 %
stage III, and 2% stage IV.
Treatment
Treatment protocols presented in national guidelines form
thebasisfortreatmentfortheSwedishpopulation.Treatment
outside protocols is rare and almost exclusively performed
within randomized controlled trials. Social security covers
costs for diagnostic work-up and treatment. The woman is
charged a minimal fee for service for screening but not for
diagnostic work-up.A fee exists also formedical visits up to
acertainsum,whichissimilarforprescribedmedication.No
patient is declined treatment for economic reasons.
The regional breast cancer database in Stockholm-Got-
land, has gathered information since 1977, when the ﬁrst
treatment protocol was implemented [34]. In 2004, 1,305
women had surgery as a primary treatment modality. The
mastectomy versus breast conservation rate was 41 vs.
58%. In 1997, sentinel lymph node biopsy was introduced
in Sweden, and all such procedures were concurrently
registered. After the completion of national feasibility and
validation studies sentinel lymph node biopsy was then
performed in selected cases (unifocal, clinically node-
negative patients with T2 \3 cm). Stockholm data from
2005 showed that sentinel node biopsy was performed in
44% (610/1,392) of all breast surgery procedures for
invasive and noninvasive cancer [35, 36]. Since 2008 a
web-based national breast cancer registry collects data on
detection, treatment, tumor-speciﬁc data, complications,
lead times, and planned treatment. The registry relates to
quality goals set by the profession and the National Board
of Health and Welfare. Sentinel node biopsy was the ﬁnal
axillary procedure in 57% of all operated breast cancers in
Sweden in 2008 (www.karolinska.se/oc).
Survival
The current overall survival rates on a national level
are 86% at 5 years and 75% at 10 years (http://www.
socialstyrelsen.se/Publicer).
Canada
Data collection and incidence estimates
Breast cancer is an important public health issue in Canada
where considerable resources are expended annually for
prevention and diagnosis at an early stage.
Annually the National Cancer Institute of Canada, the
Canadian Cancer Society, the Public Health Agency of
Canada, provincial cancer registries, and Statistics Canada,
accrue, analyze and publish the ‘‘Canadian Cancer Statis-
tics.’’ The main purpose of these published data is to pro-
vide health professionals, researchers, and policy-makers
information on common cancers in Canada with respect to
incidence, mortality, cancer distribution, and survival. Data
provided for 2007 are estimates and not actual data. These
estimates are calculated projections based on past numbers
and trends [37].
World J Surg (2010) 34:2308–2324 2317
123The most common cancer in Canadian females is breast
cancer, with an estimated 22,300 cases this year. There will
be an estimated 170 cases in males. Breast cancer contin-
ues to be the leading cause of cancer among Canadian
women at 28.9% of estimated new cases. However, lung
cancer in 2007 will continue as the leading cause of cancer
death in Canadian women at 26% of cancer-related deaths,
followed by breast at 15.5%. In 2003 subgroup analysis by
adult age group (20–49; 50–69; 70?) showed that breast
cancer was the most common female cancer in all age
groups. However, breast cancer was the leading cause of
death in young women (20–49) and ranked second in the
50–69 age group, following lung cancer. Between 1978 and
1999 the incidence of breast cancer rose steadily but has
now stabilized. This increase was probably due to an
increase in mammographic screening and improved quality
of screening during the 1980s and 1990s. The age-stan-
dardized incidence rate per 100,000 rose from 86.1 in 1978
to 104 in 2007. Other reasons contributing to the increase
in incidence are likely modiﬁable risk factors such as
increased use of hormone replacement therapy, higher
prevalence of obesity, delayed ﬁrst pregnancy or null
parity, and greater consumption of alcohol. Age-standard-
ized mortality rates have been declining since the mid
1980s, and since 1999 this trend has accelerated to 1.2%
per year. Between 1978 and 2007 the age-standardized
mortality rates per 100,000 went from 29.5 to 22.9 [38].
Earlier detection and increased use of adjuvant hor-
mones and chemotherapies have contributed to this decline.
Separating the impact of screening and treatment is chal-
lenging. In a U.S. study by Berry et al., the input of
each contributed about equally to improved breast cancer
outcomes [39].
Overall in Canada, the lifetime risk of developing breast
cancer as a woman is 11% (1 out of 9 women), and the
lifetime probability of dying from cancer is 3.7% (1 in 27
women) [38].
Survival
Long-term trends in survival from Ontario between 1975
and 1999 showed consistent improvement in survival;
however, it increased signiﬁcantly after 1989 at 0.8% per
year. The trend toward improved survival was strongest in
the age groups most affected by screening (ages 50–69)
[38]. Five-year relative survival ratios by stage of disease
are stage I 96%, stage II 86%, stage III 59%, and stage IV
26%, as recorded between 1994 and 1997 at a Canadian
regional cancer center [40]. The Canadian 5-year relative
survival rate for breast cancers diagnosed from 1995–1997
is 86% overall [37].
Analysis of hospital stays for breast cancer patients
between 1981 and 2000 by Neutel et al. demonstrated that
between 1997 and 2000 approximately 65% of cases pre-
sented locally, followed by regional presentation at 22 and
12% with distant metastases. In 1981–1984 this compared
with local presentation at 58%, regional at 14%, and distant
presentation at 28% [41].
Treatment
In the last two decades a dramatic shift in surgical practice
has brought breast-conserving surgery to the forefront. The
declining use of mastectomy for breast cancer in Canada
has been likely linked to the publication of NSABP B-06 in
March 1985, and earlier declines were probably inﬂuenced
by the Italian trials and gradual acceptance through dis-
cussion and practice of clinical trials in North America.
Further, in 1991, the National Institutes of Health in the
U.S. published its consensus conference recommendations
and its support for breast-conserving surgery in early stage
breast cancers. In 1998 when the Canadian guidelines were
ﬁrst published, the recommendations were similar to the
NIH recommendations for mastectomy and breast conser-
vation. In Canada, mastectomy rates decreased from 62.2
to 37.9 (per 100,000) between 1981 and 2000. The largest
declines occurred between 1984 and 1985. In contrast,
breast-conserving surgery rates mirrored the numbers for
mastectomy. They rose rapidly until 1986, and between
1981 and 2000, breast-conserving surgery increased from
20.4 to 38.2. In all designated time periods analyzed
between 1981 and 2000 Quebec had the lowest provincial
mastectomy rates and the highest breast-conserving surgery
rates. The Atlantic Provinces showed an opposite pattern,
whereas intermediate surgical practice patterns were
observed in the west and in Ontario [42]. Shen et al. found
that in the mid-1990s, 80% of cases were treated by mas-
tectomy and 20% by breast-conserving surgery [43].
As surgical patterns continue to evolve, sentinel node
biopsy (SLN) has also moved to the forefront. Practice
guidelines do exist in Canada, and these are rooted in the
criteria proposed by the American Society of Breast Sur-
geons and the American College of Surgeons Oncology
group. The great majority of cases are performed in a
university practice setting and by surgeons with surgical
oncology training. Rates at individual institutions vary
greatly depending on staff training, university afﬁliation,
and geographical location [44].
In the years to come we should see research showing
trends of SLN practices and how this compares with
axillary node dissection as we have seen for mastectomy
and breast-conserving surgery rates. For now in Canada
most of what we have in the literature are survey data,
which are not a reliable reﬂection of practices. Results of
randomized trials will further guide our practice of SLN
biopsy.
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Every province and territory has an organized screening
program inviting women for a biennial mammogram and
annual clinical breast exam for women 50–69 years of age.
None of the programs have achieved the nationally estab-
lished target of 70% participation; however, most prov-
inces have shown an increasing trend in participation of
these organized programs. This is most likely due to
recruitment campaigns and a greater emphasis on accessi-
bility to screening. In Canada about 61% of women
50–69 years of age reported having a screening mammo-
gram in 2003, which is a considerable increase from 53.5%
in 2000/01. Also, in some provinces, greater numbers of
women report having a screening mammogram than is the
numbers reported by the corresponding provincial pro-
gram. This is likely because screening mammography is
also available through centers not afﬁliated with organized
programs [37].
Both before and after menopause breast cancer is the
most common cancer in Canadian females. Incidence
remains high and stable, mortality is declining signiﬁcantly
at all ages, and survival is increasing.
United States
Data collection and incidence estimates
Data on breast cancer incidence, the female/male ratio of
101:1, and 5-year survival in the U.S. are taken from the
journal CA [45]. The median age of diagnosis comes from
the National Cancer Institute’s Surveillance, Epidemiol-
ogy, and End Results (SEER) database [46].
All of the data on frequency of mastectomy and lump-
ectomy come from the Memorial Sloan-Kettering Cancer
Center (MSKCC) Combined Database (comprising all
patients undergoing surgery for breast cancer at the
MSKCC), and the data on method of detection come from
the NCCN patient-reported survey given to all new patients
seen at the MSKCC for a breast cancer diagnosis. Some
caveats apply to interpreting these data. First, the data do
not distinguish between patients with DCIS and invasive
cancers; treatment is quite different in each group. Second,
the ﬁnal operation is the operation of record; a signiﬁcant
proportion of patients (perhaps 20–30%) in whom breast
conservation was attempted eventually had mastectomy for
persistently positive margins or at their own request.
Finally, the data do not examine the extent to which age,
family history, personal history of cancer, and genetic
predisposition (especially germline BRCA mutations)
affected the choice of treatment.
Recent cancer statistical publications in the United
States report that in women, breast cancer has the highest
incidence of any cancer, at 26%. The lowest incidence is in
New Mexico (115 per 100,00 per year) and the highest is in
Washington (147 per 100,000) [45]. The increased inci-
dence of breast cancer reﬂects an increased proportion of
ductal carcinoma [45]. Breast cancer incidence varies
among ethnic groups, with ‘‘Non-Hispanic White’’ having
the highest incidence, and Koreans, the lowest [47].
AJCC stage of initial presentation
There is signiﬁcant geographic variability in the initial
patterns of breast cancer presentation in the United States
[48]. From 1999 to 2003, a total of 811,652 breast cancer
patients were reported to the National Cancer Data Base of
the American College of Surgeons Commission on Cancer.
However, only 777,884 had complete stage and age
information recorded. The greatest percentage of stage I
was reported by the Northeast region at 61%, whereas the
lowest percentage was recorded in the South at 57%.
Conversely, stages III and IV disease were reported higher
in the South when compared with the rest of the United
States (11.2 vs. 10.3%) [48].
Screening and methods of detection
Mammography screening increased among all age groups
of U.S. women signiﬁcantly between 1987 and 1992.
Differences in mammography screening between black
women and white women disappeared by 1992. However,
reported screening among Hispanic women was still lower
that that of non-Hispanics. Higher education, more income,
and urban environment are associated with increased
reported mammography screening [49].
Treatment
Radiation therapy, chemotherapy, and hormonal therapy
are available to all our patients. We do not have any current
institution-based 10-year survival data; a single-surgeon
series comprised of patients treated between 1965 and 1978
at MSKCC was published in 1991 [50]. For early breast
cancer, sentinel lymph node biopsy has been adopted as a
standard approach [51–53].
Survival and mortality estimates
In the United States, cancer survival has been shown to be
correlated with income and socioeconomic status [54].
Socioeconomic status has been linked to decreased use of
optimal breast cancer care in the areas of screening, access
to treatment, access to clinical trials, co-morbidity, delivery
of care, treatment recommendations, and healthcare
workforce disparities. According to a recent Medscape
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com/viewprogram/17141), disparities in breast cancer
treatment and outcomes may be related to ethnic back-
ground, socioeconomic resources, delivery of care, tumor
biology, genetics, lifestyle, reproductive experiences,
environmental exposure, and diet and nutrition factors.
Breast cancer ranks second to lung cancer as the cause
of death among women in the United States [55]. The
mortality rate for breast cancer has decreased, however,
from 33/10,000 per year in 1991 to 25/100,000 per year in
2003, suggesting that breast cancer is being diagnosed
early and can be cured.
Discussion
Several major international congresses have been held
optimizing breast cancer care among women from several
countries, and all of them have noted East-West differences
[56]. The goal of the Breast Surgery International sympo-
sium attended by surgeons from many nations during the
2007 Montreal International Surgical Week was to discern
whether breast cancer characteristics other than incidence
differ between Asian and Western countries. The summa-
ries presented by breast cancer experts from China,
Taiwan, India, Japan, South Korea, Sweden, Canada, and
the Unite States conﬁrm previous studies in showing a
striking difference in peak incidence, which is between 40
and 50 in Asian countries, and between 60 and 70 in
Western countries. The relative contribution of biological,
genetic, and environmental factors to this difference clearly
merits further study if we are to determine whether breast
cancer is the same disease in Asia as in the West. Incidence
is increasing in Asia and in the West, but mortality is rising
in Asian countries and decreasing in the West.
Female breast cancer in the Western world has shown a
steady yearly increase of 1.5%. The most commonly cited
reasons for this increase are breast cancer awareness, early
detection by screening programs, and reliable diagnostic
tools. Screening on a national basis exists in several
countries, namely Canada, the United Kingdom, the
Netherlands, Finland, Sweden, Norway, Australia, and
Singapore. Preventive measures, and effective surgical,
endocrine, cytotoxic, and radiation therapy account for the
excellent survival data and the slight decline in mortality
during the last decade in the West. Although these coun-
tries do not represent the world as a whole, the data col-
lected give us a glimpse of the breast cancer statistics in
these countries and are a critical ﬁrst step toward broader
global representation in the future.
The importance of a global approach to breast cancer
is to share the preventive measures and appropriate
treatments from more advanced countries rapidly with
developing countries [1, 3, 56]. Although the infrastructure
for reporting cancer varies widely in the countries that
participated in the symposium, and the data often are not
representative of the entire country, important global
comparisons can still be made. The trend shown in this
report is that the incidence of breast cancer increases as
countries become more urbanized. The traditional approach
of mastectomy gives way to more lumpectomies. Although
sentinel lymph node biopsy is a standard staging procedure
[51–53] for early breast cancer in the U.S., and perhaps in
Canada and Sweden, it is still a new technique and being
evaluated in Asia.
To attempt to answer the question posed by the title of
this article—is breast cancer the same disease in Asia as in
Western countries?—we can ﬁrst take an overview of the
data presented at the ISW 2007 meeting. The differences in
the data obtained are striking. If we put to one side data on
the stage at presentation of cancer (which is most likely
related to access to service, and will be a major determinant
of survival) and look instead at incidence rates, it is clear
that incidence rates for breast cancer are uniformly lower in
Asia than they are in the West.
National cancer registry data have conﬁrmed that breast
cancer incidence rates differ between Asia and the West in
two major ways: ﬁrst, the overall rates are far lower
[57, 58]; second, the shape of the age-incidence curve is
markedly different and importantly, this difference mirrors
differences in the age-incidence distribution for ER? and
ER- breast cancers [59]. When breast cancer incidence is
plotted as a log-log plot, the linear increase in breast cancer
is inﬂected around the menopause (‘‘Clemmesen’s hook’’)
[60]. When one plots ER? and ER- breast cancers sepa-
rately, the slopes are quite distinct, with the ER? risk
continuing after the menopause, whereas the ER- clearly
diminishes [61]. This is also seen when breast cancer his-
tological subtypes are plotted independently; for example,
medullary breast cancers (which are very frequently ER-),
show a sharp falling-off in incidence after the menopause
[62]. There is also evidence for this bimodality in risk
proﬁle when intrinsic breast cancer subtypes [63], rather
than ER status, are used to subdivided breast cancers. The
median age at diagnosis for luminal A and B tumors was
74 years, whereas it was 52 years for basal and HER2?
subtypes [62], suggesting that bimodality is an essential
feature of breast cancer worldwide, and that the two main
differences between breast cancer in the West and in Asia
is the prevalence of the relevant risk factors and the access
to health care.
It is possible that some of the difference in risk proﬁles
between Western and Asian women is related to the
structure and gene expression proﬁle of the normal breast.
For example, normal breast epithelium is much more likely
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[64]. By contrast, the data on breast density is conﬂicting,
and in general, Asian women in Asia, compared with
whites in North America, seem to have low breast cancer
rates despite having small, dense breasts, although it may
be that within Asian populations, risk is proportional to
density [65]. The relationship between density and risk is
also uncertain when studying Asians born and/or living in
North America, as the data are conﬂicting [66–68], and it is
not clear if correcting for hormonal factors and body mass
index can completely explain any differences observed.
Other more general factors, such as total energy balance,
are likely to be important as well, and may interact with
breast-speciﬁc effects as well as nonspeciﬁc hormonal
‘‘drivers,’’ to modulate the risk for breast cancer. This leads
on to consider what happens when environments change
but genes stay the same.
When families move from Asia to the West, they take
their genes with them, but to a large extent, they leave their
environment behind. While, naturally, some aspects of
home life will be similar for new immigrants, they will
inevitably be exposed to the new world they ﬁnd them-
selves in. Data clearly show that when the female offspring
of Asia-born couples are brought up in North America,
their risk for breast cancer is substantially increased com-
pared with the rates observed in Asia-born Asian females
[69]. Nevertheless, incidence rates among Asia-born Asian
females are clearly increasing at a rapid pace [57, 58, 70,
71]. The only plausible explanation for these ﬁndings is
that some aspect of what is variously called urbanization,
‘‘modern living,’’ and ‘‘Westernization’’ is affecting Asian
breast cancer rates quite rapidly and probably in an irre-
versible way. This process seems to be affecting different
populations in slightly different ways.
The second way to study this phenomenon is to study a
population in which the environment is roughly the same
but the genes are different. Singapore is a city, an island,
and a state and is composed of three main ethnic groups:
Chinese, Malays, and Indians. In the past 40 years, Sin-
gapore has experienced a rapid economic growth. From
1968 to 2002, 85% of 16,178 female breast cancers in
Singapore occurred in Chinese, 10% in Malays, and 5% in
Indians. Over this time period, breast cancer has increased
year by year; by 3.1, 2.8, and 1.7% per year for Chinese,
Malays, and Indians, respectively. Despite the rather sim-
ilar external environments, current breast cancer rates are
somewhat different in the three ethnic groups, and they
have changed in different ways over the time period
studied. Essentially, what is seen is that up to age 50, rates
are lowest in Indians, but rise in a similar fashion in the
other two groups. After age 50, the pattern is different; the
rates for Indians continue to rise to age 70 years, whereas
for Chinese, and even more so for Malays, the rates
decrease. Birth cohort effects are also quite marked,
especially in the Malays, where women born in 1971–1975
have seven times the risk of breast cancer as those born in
1921–1925 [71]. Interestingly, all three populations expe-
rienced very similar and dramatic declines in fertility, but
the temporal trends in breast cancer incidence differ
between the groups, suggesting that other factors are
playing a role in determining breast cancer risk.
Asdiscussedabove,onecanspeciﬁcallyanalyzesubtypes
of breast cancer. Ideally, one would like to be able to study
many different breast cancer subtypes at the same time in
differentethnicandgeographicalsubgroups(e.g.,basal-like,
luminal-like, etc.) but this is impractical at present. It is
possible, however, to study estrogen receptor-positive
(ER?) and estrogen receptor negative (ER-) subtypes, as a
large proportion of laboratories capable of making a diag-
nosis of breast cancer will be able to offer basic immuno-
histochemical analysis for the presence or absence of the
estrogenreceptor.WhenonecomparesER?andER-breast
cancer separately, some very interesting ﬁndings emerge.
First, when considering Western countries, it is clear that
ER? and ER- breast cancers are different diseases [61].
The proportion of ER? to ER- breast cancers does
seem to differ somewhat by North American ethnic groups,
with blacks having the highest percentage of breast cancers
being of the ER-/PR- phenotype (23%), followed by
Hispanics (18.1%) and Filipinos (17.4), with Japanese and
whites having almost identical percentages (14.1 and
14.7%, respectively) Therefore, other than blacks com-
pared to all others, variations in ER status by ethnicity do
not seem to be large [72]. Interestingly, the age peak for
ER-/PR- tumors occurs much later in life for Japanese
Americans and native Hawaiians (64–65 years) than for
whites (50 years) [72]. Detailed data are generally not
available for Asian countries.
One might expect that worldwide differences in inci-
dence rates would be greater for ER? cancers than they are
for ER- cancers, but it is difﬁcult to prove this as women
in developing countries will have less access to laboratory
and imaging technologies, and this could lead to various
biases that would diminish the number of ER? breast
cancers diagnosed [73]. Nevertheless, a detailed analysis of
the literature has revealed signiﬁcant differences in the
effect of known epidemiological risk factors (such as par-
ity, age at ﬁrst birth, and body mass index) on ER?
compared with ER- breast cancer [74, 75]. In general,
ER- cancers seem somewhat insensitive to most of the
traditional risk factors associated with breast cancer,
making prediction and prevention of such cancers rather
difﬁcult. Conversely, since ER? cancers are sensitive to
‘‘lifestyle’’ factors, one would predict that is it ER? can-
cers that are going to increase rapidly in numbers in Asians
as they become more Westernized [76].
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seven conclusions:
• Rates of breast cancer are uniformly many times lower
in Asia than in the West
• The peak age of onset in Asia is 45–50 years of age,
whereas it is 55–60 years in the West
• There is a clear deﬁciency of post-menopausal ER?
breast cancers in Asians living in Asia compared with
Western populations
• The decrease in age-speciﬁc breast cancer rates with
age seen in Asian women cannot be completely
explained by a deﬁciency of ER?/PR? cases
• Outside of some special situations, there is no biolog-
ical difference in the breast cancers occurring in Asia
and the West
• The observed differences are most likely mainly
attributable to different risk factors acting differentially
on two (or more) different types of breast cancer
• As Asia becomes urbanized and Westernized, we can
expect signiﬁcant changes in the currently observed
patterns, towards Western-type data.
In response to these conclusions, the participants in the
Breast Surgery International symposium made a recom-
mendation to establish an international prospective data-
base, which could perhaps be funded by the World Health
Organization. Such a database would be a more reliable
way to determine similarities and differences in breast
cancer among women from diverse countries and different
ethnic and genetic backgrounds, as the data will be pro-
spectively collected.
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